SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-21-025519
Filing Date
2021-11-05
Accepted
2021-11-05 16:43:28
Documents
13
Period of Report
2021-11-03
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20211105_8k.htm   iXBRL 8-K 25634
  Complete submission text file 0001437749-21-025519.txt   157284

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA dffn-20211103.xsd EX-101.SCH 3593
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dffn-20211103_def.xml EX-101.DEF 11424
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dffn-20211103_lab.xml EX-101.LAB 15310
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dffn-20211103_pre.xml EX-101.PRE 11584
6 EXTRACTED XBRL INSTANCE DOCUMENT dffn20211105_8k_htm.xml XML 2575
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 211385212
SIC: 2834 Pharmaceutical Preparations